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ABSTRACT
Brain abscesses represent a group of dangerous infections typically caused by a
number of classic organisms. Group A streptococcus is a rare cause of brain abscesses
and those patients that do have this particular condition will typically have a distal
source of infection. We present a case of patient with a biopsy confirmed group A
streptococcal without a distal source of infection. His only identifiable risk factor was his
adalimumab therapy for ankylosing spondylitis. While adalimumab has not been linked
to streptococcal infection in the past, it has been associated with multiple atypical
infections and some of the consequences of its mechanism as a tissue necrosis factor
alpha inhibitor can theoretically predispose patients to streptococcal infection when
considered in conjunction with known streptococcal virulence factors. This case raises
the question of whether the patient’s adalimumab therapy may have contributed to his
unusual presentation of streptococcal infection and prompts further consideration and
study of the risks of adalimumab and other similar immunosuppressant monoclonal
antibodies.
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INTRODUCTION

CASE REPORT

Brain abscesses represent a fairly rare infectious
process with a significant risk of morbidity and
mortality. Many brain abscesses have a clear
predisposing factor and result from a select group of
common organisms. We present a case of an abscess
caused by Streptococcus pyogenes (S. pyogenes), an
organism not classically associated with abscess
formation and only found as the causative agent
of brain abscess a handful of times, in a patient
without typical predisposing factors. Additionally,
the previously reported cases have been in pediatric
patients and have been linked to contiguous spread
of infection.1 We examine whether the patient’s
long-term adalimumab, a tissue necrosis factor alpha
(TNF-a) inhibitor therapy, could have contributed to
his presentation.

Our patient is a 62-year-old male with prolonged
history of ankylosing spondylitis on adalimumab
therapy for seven months who presented with a
subacute history of progressive headaches and rightsided scotomas. He otherwise was asymptomatic
and denied fevers or other infectious symptoms.
Magnetic resonance imaging (MRI) exhibited a
3.2 cm ring-enhancing lesion in the left posterior
occipital lobe with perilesional edema (Figures 1
and 2). He underwent left occipital craniotomy
with intraoperative findings significant for
purulent material within a well-defined capsule
and intraoperative cultures grew pansensitive
Streptococcus pyogenes. Therapy with penicillin G 24
million units given via a daily continuous infusion
was initiated. The patient was discharged home after
eight days in the hospital and continued antibiotic
therapy for a total duration of eight weeks. At
follow-up, he had no residual neurologic deficits or
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FIGURE 2. Coronal MRI image showing ring-enhancing
lesion
FIGURE 1. Transverse MRI image showing ring-enhancing
lesion

complaints.
DISCUSSION
A brain abscess is defined as a pocket of infection
within the brain parenchyma and is believed to
originate from cerebritis which progresses to
a well-vascularized capsule.2 Risk factors for its
development include neurosurgical introduction of
pathogens, penetrating trauma, contiguous spread
from local infections, and hematogenous spread
from sources such as endocarditis, pneumonia, or
soft tissue infections.2,3 However, as many as 40%
of brain abscesses have no obvious predisposing
factor.2 Classical causal relationships between
risk factors and certain organisms include: dental
caries and anaerobic bacteria, trauma with either
Staphylococcus aureus (S. aureus) or Pseudomonas
aeruginosa, and hematogenous spread with S. aureus.
Notably, abscesses of hematogenous origin tend to
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be multifocal and in the distribution of the middle
cerebral artery. Symptoms may include: headache
(72-92%), nausea and vomiting (31-40%), seizure (2125%), and neurologic deficits including hemiparesis
(14-20%).4,5 Given that these symptoms are
nonspecific, brain imaging and subsequent biopsy
are required for diagnosis. Initial empiric therapy
typically includes a third generation cephalosporin,
metronidazole, and vancomycin and total duration
of therapy depends upon whether complete
surgical excision was performed and the causative
organism.6 Use of steroids and anticonvulsants
remains controversial.7
S. pyogenes is not a commonly reported abscessforming pathogen aside from the formation
of peritonsillar abscesses as a complication of
pharyngitis. However, a small number of case reports
describe S. pyogenes abscesses and postulate on
their causative factors. Genetic mutations including
CovR and RopB, two virulence factor regulators, have
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been considered and SLO mutations, a trigger of
neutrophil deactivation and apoptosis, have been
identified in S. pyogenes cultured from patients with
invasive infections.8 Non-steroidal anti-inflammatory
drugs (NSAIDs), which our patient had been taking,
have also been identified as a potential risk factor for
invasive S pyogenes infections.9
Adalimumab, a TNF-a inhibitor used in many
inflammatory conditions including ankylosing
spondylitis, Crohn’s disease, and rheumatoid arthritis
can predispose users to multiple opportunistic
infections. The most common opportunistic
infections seen with adalimumab therapy include
fungi, cytomegalovirus, Nocardia, and reactivation of
mycobacteria. TNF-a promotes neutrophil activation,
stimulates macrophage phagocytosis, and increases
production of interleukin-1 and its blockade hinders
these processes. Less predictable effects of TNF-a
inhibitors have also been documented including
apoptosis of monocytes, CD4, and CD8 T cells.10
A Cochrane review of adalimumab therapy for
ankylosing spondylitis demonstrated its efficacy
and revealed no statistically different insignificant
adverse events.11 Literature review yields many
reports of the typical opportunistic infections seen
with TNF-a inhibitors but no reports of unusual
streptococcal abscess formation. One case report did
note an intra-abdominal abscess caused by Kocuria
kristinae, a bacterium considered normal skin flora
and not known to be virulent in humans.12 Given that
our patient developed an atypical infection from a
common organism we question whether some of
these immunologic effects of TNF-a inhibitors could
have predisposed him to his condition. Although
S. pyogenes abscesses have not been reported as a
complication of TNF-a inhibitors, our patient lacked
typical risk factors for brain abscess formation and
also lacked a distal source of S. pyogenes infection.
This case report certainly does not establish a causal
link but does raise questions for further study and
analysis of future cases to determine if a link exists
between TNF-a inhibitors and unusual streptococcal
infections.
CONCLUSION
S. pyogenes has only rarely been reported as the
cause of a brain abscess. Our patient lacked typical
MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

predisposing factors for brain abscess formation
including an extracranial site of Streptococcal
infection but was on an immunosuppressive
medication. The possible contribution of
adalimumab to our patient’s illness must be
considered and the implications of a causal
relationship would be crucial in the evaluation of
patients with an intracranial lesion in the future. This
case report not only provides an interesting example
of an uncommon infection, but also prompts further
consideration and discussion of the risks associated
with novel biologic agents.
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